Skip to main content
Philogen logo

Philogen — Investor Relations & Filings

Ticker · PHIL ISIN · IT0005373789 LEI · 81560009EA1577917768 XMIL Manufacturing
Open in API
Filings indexed 377 across all filing types
Latest filing 2023-06-19 Transaction in Own Shar…
Country IT Italy
Listing XMIL PHIL

About Philogen

https://www.philogen.com

Philogen is a clinical-stage biotechnology company focused on the discovery and development of novel biopharmaceutical products for the treatment of cancer and other serious conditions associated with angiogenesis. Founded in 1996, the company's core strategy is based on innovating targeted therapies, such as antibody-cytokine fusions, which are designed to selectively deliver therapeutic agents to the site of disease. This approach aims to increase efficacy while reducing toxicity. Philogen operates as an integrated company with capabilities in research, GMP manufacturing, and clinical development of its proprietary product pipeline.

Recent filings

Filing Released Lang Actions
2023 06 19 - CS settimanale acquisto azioni proprie ITA
Transaction in Own Shares Classification · 99% confidence The document is titled "AGGIORNAMENTO SUL PROGRAMMA DI ACQUISTO DI AZIONI PROPRIE" (Update on the Share Buyback Program) and details the number of own shares purchased by Philogen S.p.A. between June 12, 2023, and June 16, 2023, including daily transaction logs. This activity—the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares'. Therefore, the appropriate filing type code is POS.
2023-06-19 Italian
2023 06 12 - CS settimanale acquisto azioni proprie ITA
Transaction in Own Shares Classification · 100% confidence The document is titled "AGGIORNAMENTO SUL PROGRAMMA DI ACQUISTO DI AZIONI PROPRIE" (Update on the Share Buyback Program) and details the number of own shares purchased by Philogen S.p.A. between June 5, 2023, and June 9, 2023, including daily transaction tables. This activity—the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares'. The code for this is POS.
2023-06-12 Italian
Allegato 3F - Maggio 2023
Director's Dealing Classification · 99% confidence The document is titled "SCHEMA DI COMUNICAZIONE DELLE OPERAZIONI SUI TITOLI" / "MODEL DISCLOSURE FOR TRANSACTIONS IN THE ISSUER'S SECURITIES". It details specific transactions (Quantità/Quantity, Prezzo Medio Ponderato/Average Weighted Price) involving the issuer's shares (AZIONE) over a reference period (05/2023), sent on 09/06/2023. This structure perfectly matches the definition of reporting personal share transactions by company directors and executives (insider trades), which corresponds to the Director's Dealing category (DIRS). Although the transactions listed are by the issuer itself (PHILOGEN S.p.A.), this specific disclosure schema is used for reporting transactions in the issuer's securities, often related to insider activity or share buybacks/issues. Given the detailed transaction breakdown and the nature of the disclosure form, DIRS (Director's Dealing) is the most appropriate fit, as it covers insider transactions, which often use similar regulatory disclosure formats, or POS (Transaction in Own Shares) if the issuer is transacting. Since the subject party (SOGGETTO) is listed as the Issuer itself (PHILOGEN S.p.A.) and the transactions are detailed daily trades, this strongly suggests a report of the company buying back or selling its own shares. Therefore, POS (Transaction in Own Shares) is a better fit than DIRS (which usually implies director/executive trades, though the form structure is similar). I will classify it as POS.
2023-06-09 Italian
2023 06 05 - CS settimanale acquisto azioni proprie ITA
Transaction in Own Shares Classification · 100% confidence The document is titled "AGGIORNAMENTO SUL PROGRAMMA DI ACQUISTO DI AZIONI PROPRIE" (Update on the Share Buyback Program) and details the number of own shares purchased by Philogen S.p.A. between May 29, 2023, and June 2, 2023, including daily transaction tables and total consideration. This activity directly relates to the company managing its own capital structure by repurchasing shares. This aligns perfectly with the definition for 'Transaction in Own Shares' (Code: POS), which covers share repurchase/issuance.
2023-06-05 Italian
Press Release Sun Pharma Philogen ENG (Price Sensitive)
Regulatory Filings Classification · 95% confidence The document is a press release dated May 30, 2023, announcing an 'Exclusive Distribution, License, and Supply Agreement' between Sun Pharma and Philogen for a specialty product, NIDLEGY™. This announcement details a business development transaction, including commercialization rights, financial sharing, and development responsibilities. This type of corporate action, which involves licensing, partnerships, or strategic alliances, is best classified under Capital/Financing Update (CAP) if it involves significant capital structure changes or, more broadly, as a Regulatory Filing (RNS) if it doesn't fit a more specific business event category. Since it is a major business agreement announcement rather than a standard financial report (like 10-K, IR, ER) or a specific corporate action like a dividend (DIV) or share repurchase (POS), and it doesn't directly relate to management changes (MANG) or director trades (DIRS), it falls best into the general category for significant corporate news that isn't explicitly covered elsewhere. However, given the nature of licensing and commercialization agreements, it often relates to future revenue streams and strategic positioning. Since there is no specific code for 'Business Development' or 'Licensing Agreement', and it is not a standard financial report, RNS (Regulatory Filings - general/miscellaneous) is the most appropriate fallback, although CAP (Capital/Financing Update) could sometimes encompass major strategic deals. Given the focus on licensing and commercialization rights, it is a significant corporate event announcement. I will classify it as RNS as it is a general corporate announcement not covered by the more specific codes like M&A (TAR) or Share Issue (SHA).
2023-05-30 English
Press Release Sun Pharma Philogen ITA (Price Sensitive)
Regulatory Filings Classification · 95% confidence The document is a press release dated May 30, 2023, announcing an exclusive commercialization, license, and supply agreement between Sun Pharmaceutical Industries Limited and Philogen S.p.A. regarding the drug Nidlegy™. This type of announcement details a strategic business transaction, partnership terms, and product development status, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a general corporate announcement regarding a business development/licensing deal. Since there is no specific category for 'Business Development Announcement' or 'Licensing Agreement,' the most appropriate fallback category is 'Regulatory Filings' (RNS), which serves as a general category for miscellaneous corporate announcements that do not fit the highly specific financial or governance codes provided. The document length (8083 chars) is substantial enough that it is the primary announcement itself, not just a notice of publication (RPA).
2023-05-30 Italian

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.